Literature DB >> 30889141

Four-factor prothrombin complex concentrate is associated with improved survival in trauma-related hemorrhage: A nationwide propensity-matched analysis.

Muhammad Zeeshan1, Mohammad Hamidi, Ara J Feinstein, Lynn Gries, Faisal Jehan, Joseph Sakran, Ashley Northcutt, Terence OʼKeeffe, Narong Kulvatunyou, Bellal Joseph.   

Abstract

INTRODUCTION: Post-traumatic hemorrhage is the most common preventable cause of death in trauma. Numerous small single-center studies have shown the superiority of four-factor prothrombin complex concentrate (4-PCC) along with fresh frozen plasma (FFP) over FFP alone in resuscitation of trauma patients. The aim of our study was to evaluate outcomes of severely injured trauma patients who received 4-PCC + FFP compared to FPP alone.
METHODS: Two-year (2015-2016) analysis of the American College of Surgeons-Trauma Quality Improvement Program database. All adult (age ≥18 years) trauma patients who received 4-PCC + FFP or FFP alone were included. We excluded patients who were on preinjury anticoagulants. Patients were stratified into two groups: 4-PCC + FFP versus FFP alone and were matched in a 1:1 ratio using propensity score matching for demographics, vitals, injury parameters, comorbidities, and level of trauma centers. Outcome measures were packed red blood cells, plasma and platelets transfused, complications, and mortality.
RESULTS: A total of 468 patients (4-PCC + FFP, 234; FFP alone, 234) were matched. Mean age was 50 ± 21 years; 70% were males; median injury severity score was 27 [20-36], and 86% had blunt injuries. Four-PCC + FFP was associated with a decreased requirement for packed red blood cells (6 units vs. 10 units; p = 0.02) and FFP (3 units vs. 6 units; p = 0.01) transfusion compared to FFP alone. Patients who received 4-PCC + FFP had a lower mortality (17.5% vs. 27.7%, p = 0.01) and lower rates of acute respiratory distress syndrome (1.3% vs. 4.7%, p = 0.04) and acute kidney injury (2.1% vs. 7.3%, p = 0.01). There was no difference in the rates of deep venous thrombosis (p = 0.11) and pulmonary embolism (p = 0.33), adverse discharge disposition (p = 0.21), and platelets transfusion (p = 0.72) between the two groups.
CONCLUSIONS: Our study demonstrates that the use of 4-PCC as an adjunct to FFP is associated with improved survival and reduction in transfusion requirements compared to FFP alone in resuscitation of severely injured trauma patients. Further studies are required to evaluate the role of addition of PCC to the massive transfusion protocol. LEVEL OF EVIDENCE: Therapeutic studies, level III.

Entities:  

Year:  2019        PMID: 30889141     DOI: 10.1097/TA.0000000000002262

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  5 in total

1.  Single-Center Use of Prothrombin Complex Concentrate in Pediatric Patients.

Authors:  Takaharu Karube; Courtney Andersen; Joseph D Tobias
Journal:  J Pediatr Intensive Care       Date:  2020-01-10

2.  Prothrombin Complex Concentrate for Trauma Induced Coagulopathy: A Systematic Review and Meta-Analysis.

Authors:  Ting-Wei Kao; Yi-Chin Lee; Hsiang-Ting Chang
Journal:  J Acute Med       Date:  2021-09-01

Review 3.  Effectiveness of prothrombin complex concentrate for the treatment of bleeding: A systematic review and meta-analysis.

Authors:  Daan P van den Brink; Mathijs R Wirtz; Ary Serpa Neto; Herbert Schöchl; Victor Viersen; Jan Binnekade; Nicole P Juffermans
Journal:  J Thromb Haemost       Date:  2020-08-02       Impact factor: 5.824

Review 4.  Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting.

Authors:  Vladimir Černý; Marc Maegele; Vanessa Agostini; Dietmar Fries; Santiago R Leal-Noval; Gábor Nardai; Giuseppe Nardi; Anders Östlund; Herbert Schöchl
Journal:  Eur J Trauma Emerg Surg       Date:  2021-01-05       Impact factor: 3.693

Review 5.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.